BioArctic AB (publ) announced that the Japanese Patent Office (JPO) is granting a new drug substance patent for the antibody BAN0805, invented by BioArctic as a potential treatment of Parkinson's disease. The patent will expire in 2041, with the possibility of a patent term extension up until 2046. The granted substance patent (based on Japanese patent application no.

2021-570377) focuses on the monoclonal antibody BAN0805, which selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while sparing the physiological monomer form of alpha-synuclein. The aim is to develop a treatment that halts or slows the progression of Parkinson's disease. At the International Congress of Parkinson's disease and movement disorders (MDS) in September 2021, results presented from the Phase 1 study with BAN0805 supported continued development of the antibody in Phase 2 with once-monthly dosing.